NASDAQ:ASND

Ascendis Pharma A/S Competitors

$124.18
-0.06 (-0.05 %)
(As of 04/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$123.82
Now: $124.18
$127.26
50-Day Range
$123.37
MA: $139.50
$158.66
52-Week Range
$120.02
Now: $124.18
$183.98
Volume179,305 shs
Average Volume205,780 shs
Market Capitalization$6.67 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Competitors

Ascendis Pharma A/S (NASDAQ:ASND) Vs. RPRX, GMAB, HZNP, CVAC, CTLT, and ALNY

Should you be buying ASND stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Ascendis Pharma A/S, including Royalty Pharma (RPRX), Genmab A/S (GMAB), Horizon Therapeutics Public (HZNP), CureVac (CVAC), Catalent (CTLT), and Alnylam Pharmaceuticals (ALNY).

Ascendis Pharma A/S (NASDAQ:ASND) and Royalty Pharma (NASDAQ:RPRX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Royalty Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65
Royalty PharmaN/AN/AN/AN/AN/A

Royalty Pharma has lower revenue, but higher earnings than Ascendis Pharma A/S.

Analyst Recommendations

This is a summary of current ratings for Ascendis Pharma A/S and Royalty Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Royalty Pharma05402.44

Ascendis Pharma A/S presently has a consensus target price of $187.6667, suggesting a potential upside of 51.12%. Royalty Pharma has a consensus target price of $51.8750, suggesting a potential upside of 24.55%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Royalty Pharma.

Institutional and Insider Ownership

40.9% of Royalty Pharma shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 2.5% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Royalty Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Royalty PharmaN/AN/AN/A

Summary

Ascendis Pharma A/S beats Royalty Pharma on 5 of the 9 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Profitability

This table compares Ascendis Pharma A/S and Genmab A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Genmab A/S50.99%34.40%30.67%

Insider & Institutional Ownership

6.2% of Genmab A/S shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Ascendis Pharma A/S and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65
Genmab A/S$804.57 million28.52$324.68 million$0.5168.59

Genmab A/S has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ascendis Pharma A/S and Genmab A/S, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Genmab A/S24802.43

Ascendis Pharma A/S presently has a consensus price target of $187.6667, indicating a potential upside of 51.12%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 20.48%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Genmab A/S.

Summary

Genmab A/S beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Risk and Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Horizon Therapeutics Public and Ascendis Pharma A/S's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion16.12$573.02 million$1.9448.20
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65

Horizon Therapeutics Public has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 4.3% of Horizon Therapeutics Public shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics Public and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Analyst Recommendations

This is a summary of recent ratings and target prices for Horizon Therapeutics Public and Ascendis Pharma A/S, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public001103.00
Ascendis Pharma A/S011102.92

Horizon Therapeutics Public presently has a consensus target price of $111.3636, suggesting a potential upside of 19.09%. Ascendis Pharma A/S has a consensus target price of $187.6667, suggesting a potential upside of 51.12%. Given Ascendis Pharma A/S's higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Horizon Therapeutics Public.

Summary

Horizon Therapeutics Public beats Ascendis Pharma A/S on 10 of the 13 factors compared between the two stocks.

CureVac (NASDAQ:CVAC) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, earnings and valuation.

Profitability

This table compares CureVac and Ascendis Pharma A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CureVacN/AN/AN/A
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%

Insider & Institutional Ownership

4.3% of CureVac shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares CureVac and Ascendis Pharma A/S's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CureVacN/AN/AN/AN/AN/A
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65

CureVac has higher earnings, but lower revenue than Ascendis Pharma A/S.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for CureVac and Ascendis Pharma A/S, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CureVac11202.25
Ascendis Pharma A/S011102.92

CureVac presently has a consensus price target of $58.3333, indicating a potential downside of 43.94%. Ascendis Pharma A/S has a consensus price target of $187.6667, indicating a potential upside of 51.12%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than CureVac.

Summary

Ascendis Pharma A/S beats CureVac on 5 of the 9 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Profitability

This table compares Ascendis Pharma A/S and Catalent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Catalent9.25%14.20%4.83%

Analyst Ratings

This is a breakdown of recent ratings for Ascendis Pharma A/S and Catalent, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Catalent01702.88

Ascendis Pharma A/S currently has a consensus target price of $187.6667, indicating a potential upside of 51.12%. Catalent has a consensus target price of $125.1250, indicating a potential upside of 12.74%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, research analysts clearly believe Ascendis Pharma A/S is more favorable than Catalent.

Institutional and Insider Ownership

97.8% of Catalent shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 1.0% of Catalent shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Catalent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65
Catalent$3.09 billion6.11$173 million$1.8859.04

Catalent has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Ascendis Pharma A/S has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.

Summary

Catalent beats Ascendis Pharma A/S on 9 of the 14 factors compared between the two stocks.

Ascendis Pharma A/S (NASDAQ:ASND) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Earnings & Valuation

This table compares Ascendis Pharma A/S and Alnylam Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascendis Pharma A/S$14.98 million445.57$-244,180,000.00($5.25)-23.65
Alnylam Pharmaceuticals$219.75 million74.22$-886,120,000.00($8.11)-17.14

Ascendis Pharma A/S has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 3.5% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Ascendis Pharma A/S and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ascendis Pharma A/S-4,042.79%-55.72%-49.42%
Alnylam Pharmaceuticals-222.19%-65.96%-31.38%

Analyst Recommendations

This is a summary of recent recommendations for Ascendis Pharma A/S and Alnylam Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ascendis Pharma A/S011102.92
Alnylam Pharmaceuticals09902.50

Ascendis Pharma A/S currently has a consensus price target of $187.6667, suggesting a potential upside of 51.12%. Alnylam Pharmaceuticals has a consensus price target of $166.4118, suggesting a potential upside of 19.70%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Alnylam Pharmaceuticals.

Risk & Volatility

Ascendis Pharma A/S has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Summary

Ascendis Pharma A/S beats Alnylam Pharmaceuticals on 9 of the 14 factors compared between the two stocks.


Ascendis Pharma A/S Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$41.65-1.1%$25.29 billionN/A0.00Increase in Short Interest
Genmab A/S logo
GMAB
Genmab A/S
1.4$34.98-0.9%$22.94 billion$804.57 million27.12Decrease in Short Interest
Analyst Revision
News Coverage
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$93.51-2.2%$20.95 billion$1.30 billion25.55Insider Selling
CureVac logo
CVAC
CureVac
0.6$104.05-1.4%$19.45 billionN/A0.00Analyst Downgrade
Unusual Options Activity
News Coverage
Gap Down
Catalent logo
CTLT
Catalent
1.7$110.99-1.0%$18.89 billion$3.09 billion70.69Unusual Options Activity
Analyst Revision
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$139.02-0.5%$16.31 billion$219.75 million-17.75
Zai Lab logo
ZLAB
Zai Lab
1.4$163.60-0.8%$14.49 billion$12.98 million-53.99Analyst Report
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$78.77-0.7%$14.32 billion$1.70 billion18.03
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$30.20-2.1%$14.28 billion$3.07 billion-52.98Analyst Report
Grifols logo
GRFS
Grifols
1.3$18.27-2.2%$12.56 billion$5.71 billion16.31Upcoming Earnings
News Coverage
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.83-0.5%$11.83 billion$16.89 billion-2.94Decrease in Short Interest
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$30.30-0.1%$10.78 billion$8.60 billion-5.56
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$64.13-1.6%$10.66 billion$2.32 billion53.00
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$168.39-1.2%$9.48 billion$2.16 billion53.12Analyst Report
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.63-0.9%$9.44 billionN/A0.00Increase in Short Interest
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.67-0.6%$8.98 billion$1.45 billion19.08Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$164.05-1.6%$8.31 billion$3.34 million-21.31News Coverage
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$54.95-1.5%$8.19 billion$40.56 million-16.11
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.4$109.58-1.5%$7.34 billion$103.71 million-24.96Analyst Revision
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$67.98-1.2%$7.06 billion$87.99 million-80.93Gap Down
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.5$218.81-0.2%$6.86 billion$311.33 million-127.21Increase in Short Interest
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$45.83-2.7%$6.44 billion$150,000.00-21.62Unusual Options Activity
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$41.03-1.9%$5.78 billion$1.12 billion85.48
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$72.63-1.1%$5.77 billion$380.83 million-9.29Analyst Report
Allakos logo
ALLK
Allakos
1.7$108.14-0.5%$5.74 billionN/A-39.47Insider Selling
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$95.95-0.9%$5.56 billion$66.51 million17.70Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.5$41.17-1.9%$5.50 billion$4.84 billion-686.05
Schrödinger logo
SDGR
Schrödinger
1.3$78.36-0.3%$5.49 billion$85.54 million0.00Insider Selling
News Coverage
Galapagos logo
GLPG
Galapagos
1.3$79.39-1.4%$5.20 billion$1.00 billion-12.03Analyst Upgrade
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$75.83-1.4%$4.70 billionN/A-6.18Analyst Revision
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.50-0.2%$4.41 billion$6.87 million-7.29Unusual Options Activity
Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.38-0.6%$4.28 billion$204.89 million-36.73
I-Mab logo
IMAB
I-Mab
1.2$57.14-3.6%$4.11 billion$4.31 million-1.98Increase in Short Interest
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.99-0.5%$4.10 billion$806.43 million-9.63Analyst Report
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47-0.0%$3.99 billion$1.11 billion23.95Analyst Report
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$55.04-3.1%$3.84 billion$117.91 million-11.16
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$46.01-18.6%$3.81 billionN/A0.00Analyst Report
Increase in Short Interest
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$77.24-1.7%$3.78 billionN/A-22.01Analyst Report
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.76-0.6%$3.60 billionN/A-6.03Analyst Report
Analyst Revision
News Coverage
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.36-1.1%$3.53 billion$114.62 million-7.81Analyst Report
Insmed logo
INSM
Insmed
1.2$33.62-1.8%$3.47 billion$136.47 million-12.93
LEGN
Legend Biotech
1.2$25.80-3.7%$3.43 billion$64.39 million0.00Decrease in Short Interest
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.20-0.4%$3.39 billion$339.08 million-12.33Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$48.19-0.6%$3.39 billion$306.98 million-6.89
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$92.20-2.7%$3.34 billion$26.52 million-8.12
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.15-0.4%$3.29 billion$36.13 million-70.37
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$117.29-1.6%$3.17 billionN/A-58.35Insider Selling
Alkermes logo
ALKS
Alkermes
1.2$19.77-2.7%$3.15 billion$1.17 billion-42.98
Arvinas logo
ARVN
Arvinas
1.5$63.00-0.2%$3.08 billion$42.98 million-24.61Gap Down
MorphoSys logo
MOR
MorphoSys
0.3$23.18-2.1%$3.05 billion$80.43 million110.39Decrease in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.